|
Top-Line Results Positive for Alemtuzumab in MS
Medscape
July 12, 2011 — Results from the first CARE-MS trial are in, and they show a 55% reduction in relapse at 2 years in adults with relapsing-remitting multiple sclerosis treated with alemtuzumab (Campath, Genzyme) compared with those receiving interferon …
See all stories on this topic »
|
|
Robert McBurney Named CEO of the Accelerated Cure Project for Multiple Sclerosis
Business Wire (press release)
(BUSINESS WIRE)–The Accelerated Cure Project for Multiple Sclerosis (ACP), a national nonprofit organization, today announced that it has named Robert McBurney, Ph.D., as its Chief Executive Officer. Dr. McBurney brings a wealth of expertise to this …
See all stories on this topic »
|
|
Multiple Sclerosis Foundation Joins Sharecare as New Content Collaborator to …
SYS-CON Media (press release)
ATLANTA, GA — (Marketwire) — 07/12/11 — In line with their mission to provide the best health and wellness information online, Sharecare today announced the addition of the Multiple Sclerosis Foundation (MSF) to their robust network of expert …
See all stories on this topic »
|
|
Canadian woman dies after undergoing controversial MS surgery
Montreal Gazette
By Matt McClure, Postmedia News July 11, 2011 CALGARY — A Calgary woman is the second Canadian to die after having an experimental vein treatment for multiple sclerosis. Within hours of having her neck veins opened at a California clinic on April 13, …
See all stories on this topic »
|
|
Positive phase III MS results from Sanofi
PMLiVE
"In this two-year comparative study, the effect of alemtuzumab on reducing relapses versus Rebif, a leading drug for the treatment of multiple sclerosis, is impressive, and the safety profile is consistent with the phase II clinical trial experience," …
See all stories on this topic »
|